Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 10/20 | 0.50 |
| ▸ | CHUK | O15111 | 6/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 2/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.34 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.34 |
| ▸ | PAK6 | Q9NQU5 | 1/20 | 0.34 |
| ▸ | PAK5 | Q9P286 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16205443 | 0.98 | CHUK (0.51) | MAP3K14CHUKDYRK1APAK4PAK1 | |
| SCHEMBL16205465 | 0.88 | CHUK (0.50) | MAP3K14CHUKPAK4PAK1PAK2 | |
| SCHEMBL18828143 | 0.85 | MAP3K14 (0.52) | MAP3K14CHUKDYRK1AMAPKAPK2 | |
| SCHEMBL16205438 | 0.84 | CHUK (0.64) | MAP3K14CHUK | |
| SCHEMBL16205453 | 0.83 | MAP3K14 (0.39) | MAP3K14CHUKPAK4PAK1PAK2 | |
| SCHEMBL16205447 | 0.81 | MAP3K14 (0.74) | MAP3K14CHUK | |
| SCHEMBL16205659 | 0.80 | CHUK (0.63) | MAP3K14CHUK | |
| SCHEMBL1612933 | 0.80 | PAK4 (0.43) | MAP3K14CHUKDYRK1APAK4PAK1 | |
| SCHEMBL16205373 | 0.78 | MAP3K14 (0.43) | MAP3K14CHUKDYRK1AMAPKAPK2 | |
| SCHEMBL16205436 | 0.77 | MAP3K14 (0.53) | MAP3K14CHUKPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-17 | — | — | US | disclosed |
| WO-2014174021-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | NFKBIA, IKBKG, MAP3K14 | MAP3K14 3/4885CHUK 25/4885DYRK1A 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.